Navigation Links
Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO

HELSINKI, Finland, November 9, 2012 /PRNewswire/ --

Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, announced today that it has appointed Frans Wuite, M.D., M.B.A, as President and Chief Executive Officer and Pekka Simula, M.Sc. (Tech) as Chief Operating Officer.

Frans Wuite brings more than 25 years of leadership experience that spans from start-up to large international companies within the biopharmaceutical industry to Oncos Therapeutics. Prior to joining Oncos, Wuite served in key leadership roles at companies in rapid growth phases. These included Warren and Araim Pharmaceuticals Inc, which he co-founded; Amgen Europe, where he spearheaded the commercial development and launch of Aranesp that rapidly became Amgen's biggest product; and the leadership of Pharmacia-Leiras, a marketing and sales joint venture in 13 European countries.

Pekka Simula, the founding CEO of Oncos since 2008, has successfully built Oncos into a clinical stage company. In his new role as Chief Operating Officer, Simula will be responsible for the company's overall program management covering research, clinical development, process development, and manufacturing.

Prior to co-founding Oncos, Simula was Global Program Manager at Varian Medical Systems (NYSE: VAR) responsible for the development and market roll-out of the company's entire oncology product suite and also held a central role in development of RapidArc™, the latest revolution in radiation oncology. Before Varian, he worked as  Project Director for CRF Health, a leading electronic Patient Reported Outcomes technology and services provider for clinical trials, and as Project Manager for Accenture.

About Oncos Therapeutics

Oncos Therapeutics develops personalized cancer immunotherapeutics based on its proprietary oncolytic adenovirus technology. The Company has clinical experience on 10 purposefully engineered vaccines. These have a direct oncolytic effect due to selective virus replication in tumor cells as well as systemic effects through vascular dissemination to metastases and induction of a strong immune response against tumor cells mediated by exposure of tumor antigens by oncolysis.  In addition, most of Oncos product candidates have a transgene that result in cytokine production in only cancer cells, e.g. GM-CSF, further enhancing the immune response against tumor cells.  Oncos' oncolytic vaccine portfolio will be focused on carefully selected cancer types that respond poorly to conventional therapies.

Based on efficacy and safety signals obtained in an Advanced Therapy Access Program (ATAP) with 290 cancer patients, for whom standard of care therapies had failed, CGTG-102 was selected as Oncos' lead product. Clinical experience with 115 CGTG-102-treated patients in ATAP has yielded important information on e.g. optimal dosing and scheduling of the product. CGTG-102 has an orphan indication as its initial target indication: First line treatment of inoperable Soft Tissue Sarcoma. CGTG-102 is currently in Phase 1 of clinical development in Europe and the United States. For more information please visit

SOURCE Oncos Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
2. ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
3. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
4. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
5. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
6. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
7. Novel technique to synthesize nanocrystals that harvest solar energy
8. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
9. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
10. Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
11. Novel clay-based coating may point the way to new generation of green flame retardants
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 nouvelles ... fois les différences entre les souches bactériennes retrouvées ... des êtres humains . Ces recherches  ouvrent ... envisager la prise en charge efficace de l,un ... chez les chats .    --> 2 ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  Connected health pioneer, Joseph C. ... of technology-enabled health and wellness, and the business opportunities ... The Internet of Healthy Things . Long ... even existed, Dr. Kvedar, vice president, Connected Health, Partners ... delivery, moving care from the hospital or doctor,s office ...
(Date:10/29/2015)... NEW YORK , Oct. 29, 2015 /PRNewswire/ ... wearable technology, announced a partnership with 2XU, a ... accessories, to deliver a smart hat with advanced ... runners and other athletes to monitor key biometrics ... of the strategic partnership, the two companies will bring ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
Breaking Biology News(10 mins):